Updated: Aug 28, 2020
Immunotherapy is a rapidly growing field in personalised medicine; in recent years we've all been impressed by the speed of growth and discovery that's marked this field, and many consider it to be the answer to modern scourges like diabetes and inflammatory conditions like arthritis or allergy. Personalised cancer drugs, such as CAR-T treatments, offer hope where it previously was in dire short supply.
However, challenges still abound - it's common knowledge in the field that it can take time to engineer and select therapeutic T-cells. It's also understood that lengthy timescales can affect both the cost of treatments and can in cases significant affect the prognosis of individual cases.
Our new technologies - #CellixTech - based on our historical expertise in microfluidics and impedance technology - have applications for human therapeutics which could pave the way to a cancer-free world.
Our #CellixTech can facilitate rapid advances in immunotherapy due to:
That speed, along with how we are improving the transfection process, offers researchers a higher yield on their efforts, and a brighter future for human health.
You may have seen Cynthia A. Challener's BioPharm article; "Cell and Gene Therapies Face Manufacturing Challenges" where Cynthia highlighted some of the most common challenges being experienced today. It's a really great read (so if you haven't read it bookmark it now!).
For ease of reference, we've a summary of the article here:
Challenges and Bottlenecks in Human Therapeutics & Drug Discovery:
1. Sterility and avoidance of adventitious agents (when producing batches from patient cells).
2. Difficulty maintaining potency
3. Expense of raw materials (such as cytokines and growth factors)
4. A lack of monitoring technologies for use during cell expansion phase
5. Sensitivity of cells to chemical transfection reagents
These are just some of the main bottlenecks in therapeutic cell expansion.
Christopher Mach, director and head of bioprocess and director of commercial operations for pharmaceutical technologies at Corning Life Sciences, notes in the article that "consistent and reliable cell isolation that doesn't introduce foreign particles is an issue." He further observes: "The same tools and platform techniques used for traditional biologics cannot be used for cell recovery. As a result, currently, cell harvesting can be a very laborious process that takes a lot of steps and has a lot of changes for things to go wrong.'